NCT04038814

Brief Summary

Ventilator-associated pneumonia (VAP) is an important cause of prolonged intensive care unit and hospital length of stay, healthcare costs and mortality in mechanically ventilated patients. There are an international guidelines for VAP diagnosis, treatment and prevention (Infectious Diseases Society of America(IDSA)/American Thoracic Society (ATS) 2016 and European Respiratory Society (ERS) / European Society of Intensive Care Medicine (ESICM) / European Society of Clinical Microbiology and Infectiuos Diseases (ESCMID) / Asociacion Latinoamericana del Torax (ALAT) 2017) routinely used in most ICUs. The investigator planed on comparing two strategies for prevention of VAP in mechanically ventilated patients: the routine VAP bundle ( historical group - VAP1) and the modified VAP bundle ( study group - VAP2) by using 3 modifications ( Shiley Evac Endotracheal tube with TaperGuard Cuff, Automatic continuous subglottic secretion drainage (SSD) and continuous tube cuff pressure monitoring). The aim of the study is an assessment of the effectiveness of the modified prevention of VAP in reduction of: early and late VAP cases, mechanical ventilation days (MV), length of stay (LOS) in the ICU, 28 day mortality and multi drug resistent pathogens (MDR) cases in adult ICU patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
386

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2019

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2019

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

July 27, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 31, 2019

Completed
Last Updated

July 31, 2019

Status Verified

July 1, 2019

Enrollment Period

1.1 years

First QC Date

July 27, 2019

Last Update Submit

July 29, 2019

Conditions

Keywords

VAPEvac Endotracheal Tube with TaperGuard CuffMDR - multi drug resistant pathogensSSD - subglottic secretion drainage,

Outcome Measures

Primary Outcomes (2)

  • Early VAP

    Total VAP cases in the ICU ( CEPPIS /Chest Echocardiography and Procalcitonin Pulmonary Infection Score/ criteria ) with early beginning of the pneumonia symptoms.

    day: 2 - 5 of mechanical ventilation

  • Late VAP

    total VAP cases in the ICU ( CEPPIS criteria ) with late beginning of the pneumonia symptoms

    day: 6 - the last day in ICU

Secondary Outcomes (5)

  • LOS

    day: 1 - the last day in the ICU, but at least 2 days

  • MV

    day: 1 - the last day in the ICU, but at least 2 days

  • nonMV

    day: 1 - the last day in the ICU,

  • Mortality

    day: 1 - 28

  • MDR

    day: 1 - the last day in the ICU,

Study Arms (2)

VAP1 - historical group

Routine prevention of VAP

Procedure: Routine prevention of VAP

VAP2 - study group

Modified prevention of VAP

Procedure: Modified prevention of VAP

Interventions

Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax

VAP1 - historical group

3 modifications of the routine bundle in the prevention of VAP: * Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes, * Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg), * Automatic continuous subglottic secretion drainage

VAP2 - study group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study group were male and female patients ( neurosurgical, cardiological, general surgical and non cardiological internal medicine type) in adult ICU. Each enrolled patient was mechanically ventilated for a period longer than 48 hours.

You may qualify if:

  • VAP2 - study group
  • mechanically ventilated patients with an artificial airways (endotracheal tube, tracheostomy tube)
  • age over 18 years
  • modified bundle in the prevention of VAP
  • VAP1 - historical group
  • mechanically ventilated patients with an artificial airways (endotracheal tube, tracheostomy tube)
  • patients hospitalised in the ICU for last 12 months before modified bundle in the prevention of VAP has been started (from 01.05.2017 to 30.04.2018)
  • age over 18 years
  • routine bundle in the prevention of VAP

You may not qualify if:

  • lack of an informed consent in awake patients in the ICU
  • age under 18 years
  • patients with no mechanical ventilation in the ICU
  • patients with probability of mechanical ventilation days and LOS in the ICU less than 48 hours
  • patients intubated and mechanically ventilated without the bundle in the prevention of VAP for a period of time longer than 12 hours before the admission to the ICU

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anaesthesiology and Intensive Care Unit St. Raphael Hospital

Krakow, Małopolska, 30-693, Poland

Location

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated

Condition Hierarchy (Ancestors)

Healthcare-Associated PneumoniaCross InfectionInfectionsPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • JAROSLAW PAWLIK, MD

    Andrzej Frycz Modrzewski Krakow University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Specialist of anaesthesiology and intensive care, An assistant of The Faculty of Medicine and Health Sciences

Study Record Dates

First Submitted

July 27, 2019

First Posted

July 31, 2019

Study Start

June 1, 2018

Primary Completion

July 1, 2019

Study Completion

July 15, 2019

Last Updated

July 31, 2019

Record last verified: 2019-07

Locations